Synaptogenix (NASDAQ: SNPX) is pleased to receive a patent from the USPTO for its innovative technique to induce synaptogenesis in humans suffering from synaptic loss.  The new technique allows intravenous administration of synaptic growth factor (SGF) activating compounds in subjects to improve synaptogenesis. Thus, regenerative therapeutics allows reversing the Alzheimer’s […]